-
公开(公告)号:FI945957A
公开(公告)日:1994-12-19
申请号:FI945957
申请日:1994-12-19
Applicant: BASF AG
Inventor: STEINER GERD , UNGER LILIANE , BEHL BERTHOLD , TESCHENDORF HANS-JUERGEN , MUNSCHAUER RAINER
IPC: C07D513/04 , A61K20060101 , A61K31/33 , A61K31/395 , A61K31/40 , A61K31/4045 , A61K31/4184 , A61K31/505 , A61K31/506 , A61K31/513 , A61K31/517 , A61K31/519 , A61K31/54 , A61K31/542 , A61P25/00 , A61P25/20 , A61P25/22 , A61P25/24 , A61P43/00 , C07D20060101 , C07D207/00 , C07D209/02 , C07D209/52 , C07D221/00 , C07D239/00 , C07D401/04 , C07D401/06 , C07D401/14 , C07D403/00 , C07D403/04 , C07D403/06 , C07D403/14 , C07D409/04 , C07D409/06 , C07D409/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07D
Abstract: PCT No. PCT/EP93/01438 Sec. 371 Date Dec. 16, 1994 Sec. 102(e) Date Dec. 16, 1994 PCT Filed Jun. 8, 1993 PCT Pub. No. WO94/00458 PCT Pub. Date Jan. 6, 1994.Abstract of the Disclosure: Compounds of the formula I I where R1, R2, n , R3, A, X, Y and Z have the meanings stated in the description, and the preparation thereof are described. The novel compounds are suitable for controlling diseases , i.e., as neuroleptics, antidepressants, sedatives, hypnotics, CNS protectives or muscle relaxants.
-
公开(公告)号:CA2156624A1
公开(公告)日:1994-10-13
申请号:CA2156624
申请日:1994-03-19
Applicant: BASF AG
Inventor: TREIBER HANS-JOERG , BEHL BERTHOLD , HOFMANN HANS PETER
IPC: C07D487/04 , A61K31/495 , A61P25/00 , A61P25/08 , A61P25/18
Abstract: Imidazolo-quinoxalinoes are used for preparing medicaments for treating diseases of the central nervous sysem. The imidazolo-quinoxalinoes have the formula (1), in which R1, R2 and X have the meanings given in the description.
-
公开(公告)号:AU5628594A
公开(公告)日:1994-07-04
申请号:AU5628594
申请日:1993-11-27
Applicant: BASF AG
Inventor: SCHLECKER RAINER , TREIBER HANS-JOERG , BEHL BERTHOLD , HOFMANN HANS PETER
IPC: A61K31/505 , A61K31/55 , A61P9/10 , A61P25/00 , A61P25/06 , A61P25/08 , A61P25/16 , A61P25/24 , A61P25/28 , C07D471/14 , C07D487/04 , C07D487/14 , C07D491/044 , C07D491/147 , C07D495/14
Abstract: Triazolopyrimidines of the formula I where A, D and X have the meanings stated in the description, and their preparation are described. The novel compounds are suitable for controlling diseases.
-
公开(公告)号:AU5628494A
公开(公告)日:1994-07-04
申请号:AU5628494
申请日:1993-11-27
Applicant: BASF AG
Inventor: SCHLECKER RAINER , TREIBER HANS-JOERG , BEHL BERTHOLD , HOFMANN HANS PETER
IPC: A61K31/505 , A61P25/02 , A61P25/20 , C07D487/04
Abstract: PCT No. PCT/EP93/03331 Sec. 371 Date Jun. 1, 1995 Sec. 102(e) Date Jun. 1, 1995 PCT Filed Nov. 27, 1993 PCT Pub. No. WO94/13672 PCT Pub. Date Jun. 23, 1994Novel triazoloquinazolines of the formula I gs stated in the description, and their preparation are described. The compounds are suitable for controlling diseases.
-
公开(公告)号:CA2151241A1
公开(公告)日:1994-06-23
申请号:CA2151241
申请日:1993-12-06
Applicant: BASF AG
Inventor: SCHLECKER RAINER , TREIBER HANS-JOERG , BEHL BERTHOLD , HOFMANN HANS PETER
IPC: C07D487/04 , A61K31/505 , A61P25/00 , A61P25/08 , A61P25/20 , A61P25/28
Abstract: Described is the use of triazoloquinazolines in the preparation of drugs for use in the treatment of diseases of the central nervous system. The triazoloquinazolines have formula (I) in which R1, R2 and X are as defined in the description.
-
公开(公告)号:FI935399A0
公开(公告)日:1993-12-02
申请号:FI935399
申请日:1993-12-02
Applicant: BASF AG
Inventor: STEINER GERD , UNGER LILIANE , BEHL BERTHOLD , TESCHENDORF HANS-JUERGEN
IPC: A61K31/40 , C07D20060101 , C07D209/52 , C07D
-
公开(公告)号:AU3988793A
公开(公告)日:1993-12-02
申请号:AU3988793
申请日:1993-05-28
Applicant: BASF AG
Inventor: LUBISCH WILFRED , BEHL BERTHOLD , HOFMANN HANS PETER
IPC: A61K31/495 , A61K31/498 , A61P25/00 , A61P25/08 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/26 , C07D241/44 , C07D241/52 , C07D401/04 , C07D403/04 , C07D487/12 , C07D487/14 , C07D403/10
Abstract: Quinoxaline-2,3-(1H,4H)diones of the general formula I in which the variables have the following meaning: R is hydrogen; an aliphatic radical having up to 12 C atoms, which can carry one of the following substituents: phenyl, cyclopentyl, cyclohexyl or a group -CO-R , -CO-O-R or -CO-NH-R , where R denotes hydrogen, C1-C4-alkyl, phenyl, benzyl or 1-phenylethyl; a cycloaliphatic radical having up to 12 C atoms, or a phenyl group, where the cyclic groups contained in R can carry up to three of the following substituents: C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, halogen, nitro, cyano, -CO-O-R and -CO-NH-R ; R is a pyrrol-1-yl group which can carry up to two of the following substituents: C1-C4-alkyl, phenyl, phenylsulphonyl, nitro, cyano and one of the groups -CO-O-R , -CO-NH-R , -CH2-O-R , -O-R and -CH=NO-R ; R is identical or different radicals from the following: C1-C4-alkyl, C1-C4-alkoxy, trifluoromethyl, trichloromethyl, trifluoromethoxy, trichloromethoxy, fluorine, chlorine, bromine, iodine, nitro, cyano and one of the groups -CO-O-R and -CO-NH-R and a fused benzene ring; n is 0 to 3. Quinoxaline-2,3-(1H,4H)diones I' in which R has the meaning mentioned. The compounds I and I' are suitable as medicines for human and veterinary medicine.
-
公开(公告)号:MX9303605A
公开(公告)日:1993-12-01
申请号:MX9303605
申请日:1993-06-16
Applicant: BASF AG
Inventor: STEINER GERD , UNGER LILIANE , BEHL BERTHOLD , TESCHENDORF HANS-JUERGEN
IPC: C07D401/04 , A61K31/40 , A61K31/403 , A61K31/4427 , A61K31/4433 , A61K31/4439 , A61K31/445 , A61P25/00 , A61P25/02 , A61P25/20 , A61P43/00 , C07D209/52 , C07D409/04 , C07D207/00
-
79.
公开(公告)号:BG63602B1
公开(公告)日:2002-06-28
申请号:BG10312299
申请日:1999-01-27
Applicant: BASF AG
Inventor: STEINER GERD , LUBISCH WILFRIED , BACH ALFRED , EMLING FRANZ , WICKE KARSTEN , TESCHENDORF HANS-JUERGEN , BEHL BERTHOLD , KERRIGAN FRANK , CHEETHAM SHARON
IPC: A61K31/435 , A61K31/519 , A61P25/24 , A61P43/00 , C07D211/00 , C07D239/00 , C07D333/00 , C07D495/14
Abstract: The 3-substituted 3,4,5,6,7.8-hexahydro-pyrido[4', 3': 4,5]-thieno [2,3-d] pyrimidine derivatives can be used as medicamentous forms for diseases where there is redud serotonin concentration and where, within the therapy, the activity of the presnaptic receptors 5-HT1B-, 5-HT1A-, 5-HT1D-, should be blocked without seriously affecting any other receptors. Depression is an example for such morbid state. The compounds have formula in which R1 is hydrogen, C1-C4-alkyl group, acetyl, benzoyl, phenylalkyl-C1-C4-residue where the aromatic residue is optionally substituted with halogen, C1-C4-alkyl, trifluoromethyl, hydroxy-, C1-C4-alkoxy-, amino-, cyano- or nitrogroups or is naphtalene-C1-C4-alkyl residue, phenylalkanon-C2-C4-residue or phenylcarbamoylalkyl-C2-residue where the phenyl group can be substituted by halogen; R2 optionally is mono-, di- or trisubstituted with halogen atoms, C1-C4-alkyl, trifluoromethyl, trifluormethoxy, hydroxy, C1-C4-alkoxy, amino-, monomethylamino-, diethylamino-, cyano- or nitrogroup, phenyl, pyridyl, pyrimidinyl or pyrasinyl reside which can optionally be ringed by one benzene ring which optionally can be mono- or disubstituted with halogen atom, C1-C4-alkyl, hydroxy, trifluormethyl, C1-C4-alkoxy, amino-, cyano- or nitrogroup, and optionally can contain one nitrogen atom or be ringed by 5- or 6-member ring which can contain one to two oxygen atoms, or can be substituted by phenyl-C1-C2-alkyl, or alkoxygroup, respectively, where the phenyl residue can be substituted with halogen, methyl, trifluormethyl or methoxygroup. A is NH or oxygen, B is hydrogen or methyl, C is hydrogen, methyl or hydroxy, X is nitrogen atom, Y is the group CH2, CH2- CH2, CH2-CH2-CH2 or CH2-CH, Z is nitrogen atom, carbon or CH where the bond between Y and Z can be double, n has the value of 2, 3 or 4. The invention also relates to physiologically acceptable salts of the above compounds. 6 claims
-
80.
公开(公告)号:AU736678B2
公开(公告)日:2001-08-02
申请号:AU4207197
申请日:1997-08-22
Applicant: BASF AG
Inventor: STEINER GERD , LUBISCH WILFRIED , BACH ALFRED , EMLING FRANZ , WICKE KARSTEN , TESCHENDORF HANS-JURGEN , BEHL BERTHOLD , KERRRIGAN FRANK , CHEETHAM SHARON
IPC: A61K31/435 , A61K31/519 , A61P25/24 , A61P43/00 , C07D211/00 , C07D239/00 , C07D333/00 , C07D495/14
Abstract: A 3-substituted 3,4,5,6,7,8-hexahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidine compound of formula IwhereinR1 is hydrogen, C1-C4-alkyl, acetyl or benzoyl, optionally substituted phenyl-C1-C4-alkyl, naphthyl-C1-C3-alkyl, phenyl-C2-C3-alkanone or a phenylcarbamoyl-C2-alkyl,R2 is optionally substituted phenyl, pyridyl, pyrimidyl or pyrazinyl, or an optionally substituted bicyclus wherein one of the two fused rings is a phenyl, a pyridyl, a pyrimidyl or a pyrazinyl ring,A is NH or oxygen,B is hydrogen or methyl,C is hydrogen, methyl or hydroxyl,X is nitrogen,Y is CH2, CH2-C2, CH2-C2-CH2 or CH2-CH,Z is nitrogen, C or CH, and the linkage between Y and Z is a single or a double bond, andn is 2, 3 or 4,or a physiologically tolerated salt thereof, and compositions comprising them and their use as antagonists of 5HT1B and 5HT1A and for the treatment of depression and related disorders.
-
-
-
-
-
-
-
-
-